Seeking Alpha·Sep 14, 2026
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptZymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zymeworks' licensing-driven revenue spike in 2025Q2 ($48.7M) has reversed sharply, with revenue falling to zero in 2026Q2 and gross margin swinging to -18.2% in 2026Q1, indicating the end of its asset-light revenue model. The company's cash burn has intensifie...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.62-7.9% vs -$0.57 | $5M+1.2% vs $5M |
Q2 2026 May 7, 2026 | -$0.59-490.0% vs -$0.10 | $2M-90.1% vs $24M |
Q2 2026 Mar 2, 2026 | -$0.55-57.1% vs -$0.35 | $3M-86.9% vs $19M |
Q4 2025 Nov 6, 2025 | -$0.26+13.3% vs -$0.30 | $28M+41.7% vs $19M |
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Jupiter Topco LLC bought a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 18,200 shares of the company's stock, valued at approximately $476,000. A number of other hedge funds have
Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition.
Bank of America Corp DE lifted its stake in Zymeworks Inc. (NASDAQ: ZYME) by 164.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,754 shares of the company's stock after buying an additional 147,230 shares during the period. Bank
Benchmark ZYME against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Zymeworks Inc. (ZYME)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.57 | $2.03B | -25.52 | 38.87% | -76.56% | -26.72% | — | |
| $37.29 | $7.7B | -13.46 | — | -7585.86% | -69.59% | — | |
| $26.87 | $3.38B | -8.17 | -4.26% | -386.32% | -87.98% | — | |
| $90.00 | $6.83B | -26.87 | -12.38% | -654.43% | -50.62% | — | |
| $34.97 | $2.08B | -4.91 | 48.03% | -418.24% | -35.67% | — | |
| $1.04 | $15.8M | -0.16 | — | — | -1270.11% | — |
Zymeworks Inc. (ZYME) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Zymeworks Inc. (ZYME) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 29, 2026·SEC
May 14, 2026·SEC
Get notified when ZYME posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Zymeworks Inc. (ZYME) stock FAQ — growth, dividends, profitability & financials explained
Zymeworks Inc. (ZYME) reported $32.5M in revenue for fiscal year 2025. This represents a 1848% increase from $1.7M in 2014.
Zymeworks Inc. (ZYME) grew revenue by 38.9% over the past year. This is strong growth.
Zymeworks Inc. (ZYME) reported a net loss of $45.12B for fiscal year 2025.
Zymeworks Inc. (ZYME) has a return on equity (ROE) of -26.7%. Negative ROE indicates the company is unprofitable.
Zymeworks Inc. (ZYME) had negative free cash flow of $166.0M in fiscal year 2025, likely due to heavy capital investments.
